Can you provide an example where the foundational approaches/formulations of CD/LD have not been satisfactory due to increasing “off time;” and, how you might deploy the scored CD/LD fractionable dosing formulation to address this clinical challenge?

Can you provide an example where the foundational approaches/formulations of CD/LD have not been satisfactory due to increasing “off time;” and, how you might deploy the scored CD/LD fractionable dosing formulation to address this clinical challenge?

CLICK HERE FOR CME CREDIT Back to Symposium

Can you provide an example where the foundational approaches/formulations of CD/LD have not been satisfactory due to increasing “off time;” and, how you might deploy the scored CD/LD fractionable dosing formulation to address this clinical challenge?

Created by

CMEducation Resources iQ&A Parkinson’s Disease (PD) Medical Intelligence Zone

Related Presenters

Laxman Bahroo, DO, FAAN

Laxman Bahroo, DO, FAAN

Associate Professor, Department of Neurology Georgetown University Medical Center Vice Chair of Finance Director, Residency Program Director, Botulinum Toxin Clinic Associate Professor of Neurology Medstar Georgetown University HospitalWashington, D.C.